2.21
2.21 (0%)
As of Feb 14, 2025
Nkarta, Inc. [NKTX]
Source:
Company Overview
Nkarta, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (925) 407-1049 |
| Industry | manufacturing |
| CEO | Paul J. Hastings |
| Website | www.nkartatx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-128.2 |
| Net Income | $-108.8 |
| Net Cash | $-3.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -24.7% |
| Profit as % of Stockholder Equity | -26.7% |
Management Effectiveness
| Return on Equity | -26.7% |
| Return on Assets | -21.7% |
| Turnover Ratio | |
| EBITA | $-128.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $501.2 |
| Total Liabilities | $93.2 |
| Operating Cash Flow | $-99.7 |
| Investing Cash Flow | $-129.6 |
| Financing Cash Flow | $226.1 |
